Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,958 total articles
Kustom Entertainment, Inc. revealed plans during a press conference to host 20+ live music and festival events at Gilley's Gambling Hall in Park City, Kansas beginning in Fall 2026, with Country Stampede Kansas 2027 scheduled for June 25-27, 2027. The company aims to diversify genres and enhance live entertainment experiences in the Wichita region,…
Rein Therapeutics has expanded its Phase 2 RENEW clinical trial for LTI-03, a novel inhaled peptide therapy targeting idiopathic pulmonary fibrosis (IPF), by enrolling its first patient in the United Kingdom. With 16 patients enrolled to date across the US, Australia, and the UK, the company plans to add two more countries to the trial soon. The st…
Magnite, the largest independent sell-side advertising company, announced the launch of Magnite Orchestration, a new coordination layer that enables automated agent-to-agent transactions leveraging AI to optimize media buying and selling. The platform integrates buyer agents with Magnite’s seller agents, allowing for enhanced discovery and activati…
NXP Semiconductors N.V. announced the approval of a $1.014 per share interim dividend for the second quarter of 2026, to be paid in July. This move signals the company's robust capital structure, confidence in its long-term growth and strong cash flow. The dividend is part of NXP's ongoing capital return program and affects shareholders of record a…
Bionano Genomics announced that 13 studies published in 2026 demonstrate the effectiveness of its optical genome mapping (OGM) technology in detecting structural genetic variants relevant to reproductive health and prenatal genetic disorders. These independent studies, involving over 700 samples, show OGM's superior ability to identify genetic caus…
InspireMD reported 30-day positive outcomes from its CGUARDIANS II clinical trial evaluating the CGuard Prime 80 cm carotid stent used in transcarotid artery revascularization (TCAR) procedures. The study demonstrated 100% acute device success without major adverse events such as death, stroke, or myocardial infarction. The company expects potentia…
VenHub Global, Inc. announced new features to improve its autonomous Smart Store shopping experience, including mobile web shopping without app downloads, guest checkout, and increased order capacity with intelligent multi-bin fulfillment. These innovations aim to simplify and speed up shopping, supporting a growing international customer base and …
Theriva Biologics announced that Phase 1 clinical trial results of VCN-01, an oncolytic adenovirus, in heavily pre-treated refractory head and neck squamous cell carcinoma patients have been published in Clinical Cancer Research. The trial demonstrated prolonged overall survival and tumor resensitization to the immune checkpoint inhibitor durvaluma…
3 E Network Technology Group Limited announced a strategic framework agreement with California-based Aladdin Alaris AI to co-develop next-generation smart healthcare and eldercare robots. The collaboration combines 3 E Network's semiconductor and edge AI chip expertise with Aladdin Alaris AI's robotics hardware and software capabilities. They aim t…
Swarmer, a NASDAQ-listed drone autonomy software company, shared a letter from Chairman Erik Prince discussing the company's strategic shift toward becoming a platform that acquires and partners with battlefield-proven defense technology firms. With its software proven in over 100,000 combat missions in Ukraine, Swarmer aims to capitalize on growin…
Immuneering Corporation has dosed the first patient in the global pivotal Phase 3 MAPKeeper 301 trial, evaluating the efficacy and safety of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone in first-line metastatic pancreatic cancer patients. The trial aims to improve overall survival and quality of life f…
Medicus Pharma Ltd. (NASDAQ: MDCX) announced submission of an Investigational New Drug (IND) application to initiate PRECISION-E2, a first-of-its-kind Phase 2a clinical trial integrating genomics to evaluate Teverelix® for symptomatic endometriosis in women in the UAE. The study combines clinical, hormonal, pharmacokinetic, and genomic data from pa…
Helus Pharma, a clinical-stage pharmaceutical company specializing in novel serotonergic agonists (NSAs) for mental health conditions, announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Conference. The company highlighted its lead drug candidates HLP003 in…
Rafael Holdings reported its Q3 fiscal 2026 financial results, highlighting the completion of the last patient last visit in its pivotal Phase 3 trial for Trappsol® Cyclo™, a treatment for Niemann-Pick Disease Type C1 (NPC). The company plans to submit a New Drug Application (NDA) in the second half of 2026, aiming to enter the commercial stage. Fi…
Cronos Group announces that its Spinach® vape portfolio has become the leading vape brand in Canada, holding a 10.4% market share as of April 2026. The company attributes this success to high product quality, innovative formulations, and advanced hardware. Cronos plans to launch new flavors and products this summer, aiming at further expanding its …
Quantum Cyber announces the creation of an Advanced Filament Manufacturing Division at its Connecticut facility to produce proprietary EMP-hardened composite filaments for its 3D printer drone production farm and external defense customers. This vertical integration aims to reduce costs, protect proprietary technology, and position the company to c…
Syndax Pharmaceuticals reported robust clinical activity of its FDA-approved menin inhibitor, Revuforj (revumenib), presented at EHA 2026. Data from real-world studies, phase 1 and 2 trials indicate high response rates and durable remissions in relapsed/refractory and newly diagnosed patients with NPM1-mutated, KMT2A-rearranged, and NUP98-rearrange…
Kyivstar Group Ltd., a Nasdaq-listed Ukrainian digital operator, announced that its ride-hailing service Uklon has launched "Uklon Store," an in-app marketplace initially offering flower delivery in Kyiv. This marks Uklon's first expansion beyond mobility services into everyday commerce, leveraging Uklon's 5.1 million active users and delivery netw…
Medifast Inc. emphasizes the unique metabolic challenges women face during perimenopause and menopause, promoting its OPTAVIA weight management program designed specifically to reduce visceral fat while preserving lean muscle. The company backs its approach with clinical research highlighting significant fat loss and muscle retention when compared …
Medifast, trading under NYSE: MED, emphasizes the scientific rigor behind its OPTAVIA weight loss program, which is backed by randomized controlled trials using clinical gold-standard DXA scanning to track body composition changes. The company highlights strong weight loss outcomes, high study completion rates, and significant fat loss with lean ma…
Kyivstar Group Ltd., a Nasdaq-listed Ukrainian digital operator, announced that its subsidiary Uklon has launched Uklon Store, an in-app marketplace starting with a Flowers category in Kyiv. This strategic move aims to accelerate ecosystem monetization by leveraging Uklon's ride-hailing infrastructure to enter e-commerce, increase user engagement, …
Relmada Therapeutics appointed Michael Quirk, PhD, a CNS drug development expert, as Senior Advisor for its sepranolone program targeting Prader-Willi Syndrome and other CNS disorders. Dr. Quirk's extensive experience in neuroactive steroid biology and translational neuroscience is expected to advance clinical development of sepranolone, a GABAA re…
The Lovesac Company reported its first quarter fiscal 2027 results with net sales largely flat compared to the prior year, driven by showroom expansion offset by shop-in-shop closures. Gross profit and margin contracted due to higher transportation and tariff costs, despite price increases and cost initiatives. The company continues to advance new …
C4 Therapeutics presented Phase 1 trial results for cemsidomide, an oral IKZF1/3 degrader, showing a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated relapsed/refractory multiple myeloma patients. The treatment was well tolerated with manageable side effects, supporting further development as a foundational therapy ac…
Tilray Brands' BrewDog is marking Scotland's national football team return with a limited-time promotion that rolls pint prices back to £2 at Scottish BrewDog bars for a 72-hour weekend and launches a £19.98 online beer bundle. This campaign aims to increase footfall, celebrate local heritage, and expand e-commerce sales, supporting BrewDog's broad…
